NASDAQ:CLNN
Clene Inc. Stock News
$0.387
-0.0005 (-0.129%)
At Close: May 10, 2024
7 Short-Squeeze Stocks To Buy In July For Contrarian Investors
04:44pm, Thursday, 08'th Jul 2021
These shares are among the stocks with the most short sell positions The post 7 Short-Squeeze Stocks To Buy In July For Contrarian Investors appeared first on InvestorPlace. More From InvestorPlace St
Clene Added to Membership of Russell 2000® Index
07:00am, Monday, 28'th Jun 2021
SALT LAKE CITY, June 28, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopha
International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer's disease
Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic Technology
07:00am, Friday, 30'th Apr 2021
IP portfolio now totals over 160 patents issued, allowed, and pending IP portfolio now totals over 160 patents issued, allowed, and pending
Clene Reports Full Year 2020 Operating and Financial Highlights
07:00am, Monday, 29'th Mar 2021
Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics
SALT LAKE CITY, March 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage bioph
Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial
08:32am, Tuesday, 09'th Mar 2021
World's first ALS platform trial led by Mass General Hospital and conducted at NEALS centers throughout the United States is a registration trial World's first ALS platform trial led by Mass General H
Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences
04:05pm, Wednesday, 03'rd Mar 2021
SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a cli
Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021
07:31am, Thursday, 25'th Feb 2021
SALT LAKE CITY, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clin
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021
07:00am, Friday, 19'th Feb 2021
SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopha
Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19
07:00am, Tuesday, 16'th Feb 2021
SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clin
Why Clene Stock Skyrocketed Today
05:14pm, Wednesday, 03'rd Feb 2021
One Wall Street analyst has high hopes for the biopharmaceutical company.
